Shares of Krystal Biotech Inc. (KRYS) surged 5.85% in premarket trading on Wednesday following the company's impressive fourth quarter 2024 financial results and positive updates on its drug pipeline.
The biotech company reported a whopping 406% year-over-year increase in net income to $1.52 per diluted share for Q4, handily beating analyst estimates of $1.16. Revenue soared 116% to $91.1 million, driven by growing sales of VYJUVEK, the first-ever FDA-approved redosable gene therapy for dystrophic epidermolysis bullosa (DEB).
For the full year 2024, VYJUVEK net product revenue skyrocketed 473% to $290.5 million. Krystal ended the year with a robust balance sheet, holding $749.6 million in cash and investments to fund its ambitious drug development plans.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。